Gameto Expands Executive Team with the Appointment of David McCulloh, Ph.D., H.C.L.D., C.C. as Vice President of Embryology
Retrieved on:
Tuesday, January 10, 2023
Work, Gynaecology, IVF, Obstetrics, Pain, Egg, Fertility, Medical school, Research, Cell engineering, Sport, Mood Swings, Reproductive medicine, McCulloh, Department of Obstetrics and Gynecology (Massachusetts General Hospital), New York University Grossman School of Medicine, Constipation, ART, Reproduction, University of Miami Division of Surgical Neurooncology, Nausea, Hospital, Oregon Health & Science University, Faculty, Weight gain, Bloating, RMA, University, Therapy, Laboratory, New Jersey Medical School, Lab, Human, School, NYU, Woman, Oocyte, Pharmaceutical industry, Birth control, Embryology
NEW YORK, Jan. 10, 2023 /PRNewswire/ -- Gameto, a biotechnology company using cell engineering to develop therapeutics for diseases of the female reproductive system, today announced the appointment of David McCulloh, Ph.D., H.C.L.D., C.C. as Vice President of Embryology.
Key Points:
- NEW YORK, Jan. 10, 2023 /PRNewswire/ -- Gameto, a biotechnology company using cell engineering to develop therapeutics for diseases of the female reproductive system, today announced the appointment of David McCulloh, Ph.D., H.C.L.D., C.C.
- as Vice President of Embryology.
- "We are thrilled to have David join our team in New York," said Dina Radenkovic, co-founder and CEO of Gameto.
- "Gameto's focus on developing a therapeutic that makes IVF and egg freezing shorter, safer, and more effective captivated my attention.